Ask AI
HNSCC Therapeutic Strategies

CE / CME

HNSCC: Current and Emerging Therapeutic Strategies

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: May 29, 2026

Expiration: November 28, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How many people with HNSCC do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Based on available evidence and approved indications patients with resectable, locally advanced HNSCC and which of the following levels of PD-L1 expression would benefit from perioperative (neoadjuvant and adjuvant) pembrolizumab?

4.

Which of the following most accurately describes the EGFR targeting antibody(ies) with demonstrated activity as monotherapy in patients with recurrent HNSCC following PD-1 and chemotherapy?